Multi-targeted therapy of cancer by genistein

Cancer Letters

Volumn 269, Issue 2, 2008, Pages 226-242

  Banerjee, Sanjeev ^a   Li, Yiwei ^a   Wang, Zhiwei ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Cancer therapy; Chemoprevention; Chemosensitization; Genistein; NF B

Indexed keywords

ANDROGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ESTROGEN; GEMCITABINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; PREDNISONE; PROTEIN KINASE B; VINCRISTINE;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL SURVIVAL; CHEMICAL STRUCTURE; DIET SUPPLEMENTATION; ESTROGEN ACTIVITY; FOOD DRUG INTERACTION; HOMEOSTASIS; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; SHORT SURVEY;

ANIMALIA;

EID: 48749117943     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.052     Document Type: Review

References (146)

1. Lampe J.W., Nishino Y., Ray R.M., Wu C., Li W., Lin M.G., et al. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2579-2586
2. Adlercreutz H., Markkanen H., and Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342 (1993) 1209-1210
3. Mills P.K., Beeson W.L., Phillips R.L., and Fraser G.E. Cohort study of diet lifestyle and prostate cancer in Adventist men. Cancer 64 (1989) 598-604
4. Kurahashi N., Iwasaki M., Sasazuki S., Otani T., Inoue M., and Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 538-545
5. Jacobsen B.K., Knutsen S.F., and Fraser G.E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 9 (1998) 553-557
6. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 (1998) 4252-4263
7. Knight D.C., and Eden J.A. A review of the clinical effects of phytoestrogens. Obstet. Gynecol. 87 (1996) 897-904
8. Zava D.T., Dollbaum C.M., and Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc. Soc. Exp. Biol. Med. 217 (1998) 369-378
9. Joshi J.V., Vaidya R.A., Pandey S.N., Agashe S., Chandrasekharan S., Menon S.K., et al. Plasma levels of genistein following a single dose of soy extract capsule in Indian women. Indian J. Med. Res. 125 (2007) 534-541
10. Takimoto C.H., Glover K., Huang X., Hayes S.A., Gallot L., Quinn M., et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1213-1221
11. Russo A., Cardile V., Lombardo L., Vanella L., and Acquaviva R. Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells. J. Nutr. Biochem. 17 (2006) 103-108
12. Si H., and Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr. Med. Chem. 14 (2007) 2581-2589
13. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M., et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann. Intern. Med. 146 (2007) 839-847
14. Szkudelska K., and Nogowski L. Genistein - a dietary compound inducing hormonal and metabolic changes. J. Steroid. Biochem. Mol. Biol. 105 (2007) 37-45
15. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
16. Sakla M.S., Shenouda N.S., Ansell P.J., Macdonald R.S., and Lubahn D.B. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine 32 (2007) 69-78
17. Abler A., Smith J.A., Randazzo P.A., Rothenberg P.L., and Jarett L. Genistein differentially inhibits postreceptor effects of insulin in rat adipocytes without inhibiting the insulin receptor kinase. J. Biol. Chem. 267 (1992) 3946-3951
18. Okura A., Arakawa H., Oka H., Yoshinari T., and Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun. 157 (1988) 183-189
19. Evans B.A., Griffiths K., and Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J. Endocrinol. 147 (1995) 295-302
20. Huang J., Nasr M., Kim Y., and Matthews H.R. Genistein inhibits protein histidine kinase. J. Biol. Chem. 267 (1992) 15511-15515
21. Ruiz-Larrea M.B., Mohan A.R., Paganga G., Miller N.J., Bolwell G.P., and Rice-Evans C.A. Antioxidant activity of phytoestrogenic isoflavones. Free Radic. Res. 26 (1997) 63-70
22. Zhou Y., and Lee A.S. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J. Natl. Cancer Inst. 90 (1998) 381-388
23. Peterson G., and Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Diff. 7 (1996) 1345-1351
24. Peterson G., and Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22 (1993) 335-345
25. Li Y., and Sarkar F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 8 (2002) 2369-2377
26. Fang M.Z., Chen D., Sun Y., Jin Z., Christman J.K., and Yang C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 11 (2005) 7033-7041
27. Cabanes A., Wang M., Olivo S., DeAssis S., Gustafsson J.A., Khan G., et al. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 25 (2004) 741-748
28. Constantinou A., Kiguchi K., and Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res. 50 (1990) 2618-2624
29. Buckley A.R., Buckley D.J., Gout P.W., Liang H., Rao Y.P., and Blake M.J. Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. Mol. Cell Endocrinol. 98 (1993) 17-25
30. Matsukawa Y., Marui N., Sakai T., Satomi Y., Yoshida M., Matsumoto K., et al. Genistein arrests cell cycle progression at G2-M. Cancer Res. 53 (1993) 1328-1331
31. Pagliacci M.C., Smacchia M., Migliorati G., Grignani F., Riccardi C., and Nicoletti I. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur. J. Cancer 30A (1994) 1675-1682
32. Casagrande F., and Darbon J.M. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp. Cell Res. 258 (2000) 101-108
33. Davis J.N., Singh B., Bhuiyan M., and Sarkar F.H. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer 32 (1998) 123-131
34. Lian F., Bhuiyan M., Li Y.W., Wall N., Kraut M., and Sarkar F.H. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer 31 (1998) 184-191
35. Upadhyay S., Neburi M., Chinni S.R., Alhasan S., Miller F., and Sarkar F.H. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin. Cancer Res. 7 (2001) 1782-1789
36. Kuzumaki T., Kobayashi T., and Ishikawa K. Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun. 251 (1998) 291-295
37. Li Y., Upadhyay S., Bhuiyan M., and Sarkar F.H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18 (1999) 3166-3172
38. Li Y., Bhuiyan M., and Sarkar F.H. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int. J. Oncol. 15 (1999) 525-533
39. Alhasan S.A., Pietrasczkiwicz H., Alonso M.D., Ensley J., and Sarkar F.H. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr. Cancer 34 (1999) 12-19
40. Touny L.H., and Banerjee P.P. Identification of both Myt-1 and Wee-1 as necessary mediators of the p21-independent inactivation of the cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein. Prostate 66 (2006) 1542-1555
41. Banerjee S., Zhang Y., Wang Z., Che M., Chiao P.J., Abbruzzese J.L., et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int. J. Cancer 120 (2007) 906-917
42. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 65 (2005) 9064-9072
43. Spinozzi F., Pagliacci M.C., Migliorati G., Moraca R., Grignani F., Riccardi C., et al. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 18 (1994) 431-439
44. Kyle E., Neckers L., Takimoto C., Curt G., and Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol. 51 (1997) 193-200
45. Moiseeva E.P., Almeida G.M., Jones G.D., and Manson M.M. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol. Cancer Ther. 6 (2007) 3071-3079
46. Tophkhane C., Yang S., Bales W., Archer L., Osunkoya A., Thor A.D., et al. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int. J. Oncol. 31 (2007) 867-874
47. Katdare M., Osborne M., and Telang N.T. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells. Int. J. Oncol. 21 (2002) 809-815
48. Kazi A., Daniel K.G., Smith D.M., Kumar N.B., and Dou Q.P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem. Pharmacol. 66 (2003) 965-976
49. Yeh T.C., Chiang P.C., Li T.K., Hsu J.L., Lin C.J., Wang S.W., et al. Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochem. Pharmacol. 73 (2007) 782-792
50. Davis J.N., Kucuk O., and Sarkar F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr. Cancer 35 (1999) 167-174
51. Alhasan S.A., Ensley J.F., and Sarkar F.H. Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int. J. Oncol. 16 (2000) 333-338
52. Natarajan K., Manna S.K., Chaturvedi M.M., and Aggarwal B.B. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Arch. Biochem. Biophys. 352 (1998) 59-70
53. Davis J.N., Kucuk O., Djuric Z., and Sarkar F.H. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic. Biol. Med. 30 (2001) 1293-1302
54. Karin M., and Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin. Immunol. 12 (2000) 85-98
55. Lee F.S., Peters R.T., Dang L.C., and Maniatis T. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc. Natl. Acad. Sci. USA 95 (1998) 9319-9324
56. Sarkar F.H., and Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 66 (2006) 3347-3350
57. Mohammad R.M., Banerjee S., Li Y., Aboukameel A., Kucuk O., and Sarkar F.H. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 106 (2006) 1260-1268
58. Li Y., Ellis K.L., Ali S., El-Rayes B.F., Nedeljkovic-Kurepa A., Kucuk O., et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28 (2004) e90-e95
59. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., and Sarkar F.H. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 66 (2006) 4816-4825
60. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
61. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
62. Yang C.H., Murti A., Pfeffer S.R., Kim J.G., Donner D.B., and Pfeffer L.M. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 276 (2001) 13756-13761
63. Stoica G.E., Franke T.F., Wellstein A., Czubayko F., List H.J., Reiter R., et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol. Endocrinol. 17 (2003) 818-830
64. Stoica G.E., Franke T.F., Wellstein A., Morgan E., Czubayko F., List H.J., et al. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 22 (2003) 2073-2087
65. El Touny L.H., and Banerjee P.P. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis 28 (2007) 1710-1717
66. Montgomery J.S., Price D.K., and Figg W.D. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol. 195 (2001) 138-146
67. Kupelian P., Katcher J., Levin H., Zippe C., and Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48 (1996) 249-260
68. Luke M.C., and Coffey D.S. Human androgen receptor binding to the androgen response element of prostate specific antigen. J. Androl. 15 (1994) 41-51
69. Sato N., Gleave M.E., Bruchovsky N., Rennie P.S., Goldenberg S.L., Lange P.H., et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J. Steroid Biochem. Mol. Biol. 58 (1996) 139-146
70. Davis J.N., Muqim N., Bhuiyan M., Kucuk O., Pienta K.J., and Sarkar F.H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int. J. Oncol. 16 (2000) 1091-1097
71. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18 (1999) 4608-4618
72. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J. 9 (1995) 726-735
73. Sebolt-Leopold J.S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19 (2000) 6594-6599
74. Kong A.N., Yu R., Hebbar V., Chen C., Owuor E., Hu R., et al. Signal transduction events elicited by cancer prevention compounds. Mutat. Res. 480-481 (2001) 231-241
75. Huang X., Chen S., Xu L., Liu Y., Deb D.K., Platanias L.C., et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65 (2005) 3470-3478
76. Kim E.K., Kwon K.B., Song M.Y., Seo S.W., Park S.J., Ka S.O., et al. Genistein protects pancreatic beta cells against cytokine-mediated toxicity. Mol. Cell Endocrinol. 278 (2007) 18-28
77. Lee M.W., Bach J.H., Lee H.J., Lee D.Y., Joo W.S., Kim Y.S., et al. The activation of ERK1/2 via a tyrosine kinase pathway attenuates trail-induced apoptosis in HeLa cells. Cancer Invest. 23 (2005) 586-592
78. Wei H., Wei L., Frenkel K., Bowen R., and Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr. Cancer 20 (1993) 1-12
79. Rotondo S., Krauze-Brzosko K., Manarini S., Martelli N., Pecce R., Evangelista V., et al. Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake. Br. J. Nutr. (2007) 1-8
80. Hernandez-Montes E., Pollard S.E., Vauzour D., Jofre-Montseny L., Rota C., Rimbach G., et al. Activation of glutathione peroxidase via Nrf1 mediates genistein's protection against oxidative endothelial cell injury. Biochem. Biophys. Res. Commun. 346 (2006) 851-859
81. Kameoka S., Leavitt P., Chang C., and Kuo S.M. Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett. 146 (1999) 161-167
82. Dudek E.J., Shang F., and Taylor A. H(2)O(2)-mediated oxidative stress activates NF-kappa B in lens epithelial cells. Free Radic. Biol. Med. 31 (2001) 651-658
83. Lau T.Y., and Leung L.K. Soya isoflavones suppress phorbol 12-myristate 13-acetate-induced COX-2 expression in MCF-7 cells. Br. J. Nutr. 96 (2006) 169-176
84. Hwang J.T., Ha J., and Park O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem. Biophys. Res. Commun. 332 (2005) 433-440
85. Raffoul J.J., Banerjee S., Singh-Gupta V., Knoll Z.E., Fite A., Zhang H., et al. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res. 67 (2007) 2141-2149
86. Su Y., Simmen F.A., Xiao R., and Simmen R.C. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol. Genom. 30 (2007) 8-16
87. Hawrylewicz E.J., Zapata J.J., and Blair W.H. Soy and experimental cancer: animal studies. J. Nutr. 125 (1995) 698S-708S
88. Ravindranath M.H., Muthugounder S., Presser N., and Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 546 (2004) 121-165
89. Fritz W.A., Coward L., Wang J., and Lamartiniere C.A. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 19 (1998) 2151-2158
90. Sharma O.P., Adlercreutz H., Strandberg J.D., Zirkin B.R., Coffey D.S., and Ewing L.L. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J. Steroid Biochem. Mol. Biol. 43 (1992) 557-564
91. Onozawa M., Kawamori T., Baba M., Fukuda K., Toda T., Sato H., et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn. J. Cancer Res. 90 (1999) 393-398
92. Tanaka T., Kohno H., Tanino M., and Yanaida Y. Inhibitory effects of estrogenic compounds, 4-nonylphenol and genistein, on 7,12-dimethylbenz[a]anthracene-induced ovarian carcinogenesis in rats. Ecotoxicol. Environ. Saf. 52 (2002) 38-45
93. Landstrom M., Zhang J.X., Hallmans G., Aman P., Bergh A., Damber J.E., et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 36 (1998) 151-161
94. Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., and Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 129 (1999) 1628-1635
95. Li D., Yee J.A., McGuire M.H., Murphy P.A., and Yan L. Soybean isoflavones reduce experimental metastasis in mice. J. Nutr. 129 (1999) 1075-1078
96. Lamartiniere C.A., Moore J.B., Brown N.M., Thompson R., Hardin M.J., and Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis 16 (1995) 2833-2840
97. Uckun F.M., Evans W.E., Forsyth C.J., Waddick K.G., Ahlgren L.T., Chelstrom L.M., et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267 (1995) 886-891
98. Singh A.V., Franke A.A., Blackburn G.L., and Zhou J.R. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res. 66 (2006) 1851-1858
99. Wei H., Saladi R., Lu Y., Wang Y., Palep S.R., Moore J., et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. J. Nutr. 133 (2003) 3811S-3819S
100. Shyong E.Q., Lu Y., Lazinsky A., Saladi R.N., Phelps R.G., Austin L.M., et al. Effects of the isoflavone 4′,5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. Carcinogenesis 23 (2002) 317-321
101. Begum M., Tashiro H., Katabuchi H., Suzuki A., Kurman R.J., and Okamura H. Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab. Invest. 86 (2006) 286-296
102. Tatsuta M., Iishi H., Baba M., Yano H., Uehara H., and Nakaizumi A. Attenuation by genistein of sodium-chloride-enhanced gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int. J. Cancer 80 (1999) 396-399
103. Tan M., Yao J., and Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57 (1997) 1199-1205
104. Fotsis T., Pepper M., Adlercreutz H., Hase T., Montesano R., and Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr. 125 (1995) 790S-797S
105. Owen J.L., Torroella-Kouri M., and Iragavarapu-Charyulu V. Molecular events involved in the increased expression of matrix metalloproteinase-9 by T lymphocytes of mammary tumor-bearing mice. Int. J. Mol. Med. 21 (2008) 125-134
106. Li Y., and Sarkar F.H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 186 (2002) 157-164
107. Xu L., and Bergan R.C. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Mol. Pharmacol. 70 (2006) 869-877
108. Lee W.Y., Huang S.C., Tzeng C.C., Chang T.L., and Hsu K.F. Alterations of metastasis-related genes identified using an oligonucleotide microarray of genistein-treated HCC1395 breast cancer cells. Nutr. Cancer 58 (2007) 239-246
109. Li Y., Che M., Bhagat S., Ellis K.L., Kucuk O., Doerge D.R., et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 6 (2004) 354-363
110. Iwasaki T., Mukai M., Tsujimura T., Tatsuta M., Nakamura H., Terada N., et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int. J. Cancer 100 (2002) 381-387
111. Zhou J.R., Yu L., Zhong Y., Nassr R.L., Franke A.A., Gaston S.M., et al. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate 53 (2002) 143-153
112. Miekus K., and Madeja Z. Genistein inhibits the contact-stimulated migration of prostate cancer cells. Cell Mol. Biol. Lett. 12 (2007) 348-361
113. Craft C.S., Xu L., Romero D., Vary C.P., and Bergan R.C. Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Mol. Pharmacol. 73 (2008) 235-242
114. El Touny L.H., and Banerjee P.P. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem. Biophys. Res. Commun. 361 (2007) 169-175
115. Roberts A.B., Flanders K.C., Heine U.I., Jakowlew S., Kondaiah P., Kim S.J., et al. Transforming growth factor-beta: multifunctional regulator of differentiation and development. Philos. Trans. R. Soc. Lond. B Biol. Sci. 327 (1990) 145-154
116. Kim H., Peterson T.G., and Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr. 68 (1998) 1418S-1425S
117. Su S.J., Yeh T.M., Chuang W.J., Ho C.L., Chang K.L., Cheng H.L., et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem. Pharmacol. 69 (2005) 307-318
118. Guo Y., Wang S., Hoot D.R., and Clinton S.K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J. Nutr. Biochem. 18 (2007) 408-417
119. Mohammad R.M., Al-Katib A., Aboukameel A., Doerge D.R., Sarkar F., and Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol. Cancer Ther. 2 (2003) 1361-1368
120. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65 (2005) 6934-6942
121. El-Rayes B.F., Ali S., Ali I.F., Philip P.A., Abbruzzese J., and Sarkar F.H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 66 (2006) 10553-10559
122. Mai Z., Blackburn G.L., and Zhou J.R. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol. Carcinog. 46 (2007) 534-542
123. Vinall R.L., Hwa K., Ghosh P., Pan C.X., Lara Jr. P.N., and de Vere White R.W. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin. Cancer Res. 13 (2007) 6204-6216
124. Shen J., Tai Y.C., Zhou J., Stephen Wong C.H., Cheang P.T., Fred Wong W.S., et al. Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp. Hematol. 35 (2007) 75-83
125. Satoh H., Nishikawa K., Suzuki K., Asano R., Virgona N., Ichikawa T., et al. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res. Commun. Mol. Pathol. Pharmacol. 113-114 (2003) 149-158
126. Tanos V., Brzezinski A., Drize O., Strauss N., and Peretz T. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol. 102 (2002) 188-194
127. Lee R., Kim Y.J., Lee Y.J., and Chung H.W. The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Toxicology 195 (2004) 87-95
128. Khoshyomn S., Manske G.C., Lew S.M., Wald S.L., and Penar P.L. Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. Pediatr. Neurosurg. 33 (2000) 123-131
129. Novak-Hofer I. The L1 cell adhesion molecule as a target for radioimmunotherapy. Cancer Biother. Radiopharm. 22 (2007) 175-184
130. Nozawa F., Itami A., Saruc M., Kim M., Standop J., Picha K.S., et al. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas 29 (2004) 45-52
131. Jin C.Y., Park C., Cheong J., Choi B.T., Lee T.H., Lee J.D., et al. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett. 257 (2007) 56-64
132. Hillman G.G., Forman J.D., Kucuk O., Yudelev M., Maughan R.L., Rubio J., et al. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin. Cancer Res. 7 (2001) 382-390
133. Hillman G.G., Wang Y., Che M., Raffoul J.J., Yudelev M., Kucuk O., et al. Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer 7 (2007) 4
134. Akimoto T., Nonaka T., Ishikawa H., Sakurai H., Saitoh J.I., Takahashi T., et al. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 195-201
135. Yashar C.M., Spanos W.J., Taylor D.D., and Gercel-Taylor C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol. Oncol. 99 (2005) 199-205
136. Constantinou A.I., Mehta R., and Husband A. Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. Eur. J. Cancer 39 (2003) 1012-1018
137. Alvero A.B., O'Malley D., Brown D., Kelly G., Garg M., Chen W., et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 106 (2006) 599-608
138. Sapi E., Alvero A.B., Chen W., O'Malley D., Hao X.Y., Dwipoyono B., et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol. Res. 14 (2004) 567-578
139. Sarkar F.H., Adsule S., Padhye S., Kulkarni S., and Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem. 6 (2006) 401-407
140. Fu X.H., Wang L., Zhao H., Xiang H.L., and Cao J.G. Synthesis of genistein derivatives and determination of their protective effects against vascular endothelial cell damages caused by hydrogen peroxide. Bioorg. Med. Chem. Lett. (2007)
141. Li H.Q., Ge H.M., Chen Y.X., Xu C., Shi L., Ding H., et al. Synthesis and cytotoxic evaluation of a series of genistein derivatives. Chem. Biodivers. 3 (2006) 463-472
142. Fischer L., Mahoney C., Jeffcoat A.R., Koch M.A., Thomas B.E., Valentine J.L., et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr. Cancer 48 (2004) 160-170
143. Miltyk W., Craciunescu C.N., Fischer L., Jeffcoat R.A., Koch M.A., Lopaczynski W., et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am. J. Clin. Nutr. 77 (2003) 875-882
144. Kumar N.B., Krischer J.P., Allen K., Riccardi D., Besterman-Dahan K., Salup R., et al. A phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr. Cancer 59 (2007) 163-168
145. Vaishampayan U., Hussain M., Banerjee M., Seren S., Sarkar F.H., Fontana J., et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr. Cancer 59 (2007) 1-7
146. Dalais F.S., Meliala A., Wattanapenpaiboon N., Frydenberg M., Suter D.A., Thomson W.K., et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 64 (2004) 510-515